The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index; 35 of the 231 sources its claims cite were checked for support.
Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document
Open accessAbstract
Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 µg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.
Overview
CoChat Summary
## TL;DR
This consensus document does not report a new clinical trial; it synthesizes prior basic, translational, and clinical evidence to guide future LT4/LT3 combination-therapy trials in hypothyroidism. The authors conclude that prior trials were heterogeneous and often underoptimized, and they recommend better patient selection, thyroid-specific patient-reported outcomes, and more physiological dosing/monitoring strategies.
## Key findings
- The paper states that 14 clinical trials of LT4/LT3 combination therapy had not shown a consistent benefit.
- Of 34 Consensus Statements available for voting, 28 achieved agreement from at least 75% of the group, and 13 reached 100% consensus.
- The paper reports that among prior combination-therapy trials, 2 trials contributing 92 participants showed superiority of combination therapy on multiple QoL/mood measures, 2 trials contributing 633 participants showed superiority on a minority of measures, and the remaining 9 trials showed no benefit.
- For neurocognitive outcomes, 1 trial of 33 patients showed benefit on multiple measures, 1 trial of 26 participants showed benefit on a minority of measures, and 8 trials showed no benefit; the paper also notes prior trial ratios ranged from 4:1 to 19:1 T4:T3, and LT3/T3 pharmacologic equivalence was estimated at about 1:3.
## Methods
- Consensus document based on a joint ATA/BTA/ETA symposium held on November 3, 2019, with presentations and input from 12 content experts, followed by workshops, synthesis of material into summary statements, and iterative voting/revision.
- The source material was organized into 11 topics; 34 Consensus Statements were drafted and voted on by the authors.
- The paper is a narrative consensus/review, drawing on prior clinical trials, mechanistic studies, and modeling rather than reporting original participant-level trial data.
## Limitations
- The paper itself states that prior studies had small sample sizes, short duration, multiple comparisons, once-daily LT3 dosing, and heterogeneous dosing/outcome measures, which made results hard to compare or meta-analyze.
- It also states that patient preference was not validated with adequate PRO measures in earlier trials, and that many trials did not specifically recruit patients dissatisfied with LT4 or with persistent symptoms.
- Evident from the text: this is a consensus/review document, so its recommendations are not direct evidence from a new randomized trial; they depend on the quality and heterogeneity of the cited literature.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Valid · 14 Not valid · 124 Not checked · 70 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Also in pituitary thyrotrophs, the loss of D2 activity caused by T4 is a much slower process [5].”
What the sources say
- Partly supportedcites [4] Werneck de Castro, 2015, Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine, J Clin Invest sourceExperimental — accuracy not yet measured
The Figure 5 explanation (p. 10) says T4-induced D2 inactivation is insignificant in the hypothalamus and readily occurs in peripheral tissues. It places pituitary thyrotrophs *probably* between those extremes, based on previously published data. That supports a possible difference in thyrotrophs, but not the unqualified claim that their loss of D2 activity is a much slower process. (LLM, conf=0.85)
- Not checked yetcites [5] Christoffolete, 2006, Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism, Endocrinology source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In LT4-treated thyroidectomized patients to achieve normal serum TSH levels, the D2 pathway contributes with ∼ 80% of the circulating T3 [6].”
What the sources say
- Partly supportedcites [6] Saberi, 1975, Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man, J Clin Invest sourceExperimental — accuracy not yet measured
Our copy supports only the qualitative core: the Introduction (p. 218) states that 'a large portion of the serum T3 is produced as a result of extrathyroidal conversion from T4', and the Discussion (p. 221) that PTU lowered serum T3 'in patients whose major, if not sole, source of T3 is orally administered T4'. However, no passage gives a magnitude (~80%), and nothing mentions a D2/type 2 deiodinase pathway (the enzyme was not characterized in 1975; the paper's evidence is pharmacological inhibition of T4-to-T3 conversion by PTU). The population qualifier also does not match: the Methods (p. 219) describe 10 patients with thyroidal hypothyroidism (idiopathic 4, Hashimoto's 4, 131I 1, thyroidectomy for carcinoma only 1) on fixed 0.1 or 0.2 mg T4, not thyroidectomized patients titrated to normal TSH — indeed mean TSH in the 0.1 mg group was elevated (29.6 µU/ml) and did not normalize. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interference with proper signaling is best illustrated in patients with Allan-Herndon Dudley syndrome [41].”
What the sources say
- Supportedcites [41] Groeneweg, 2020, Thyroid Hormone Transporters, Endocr Rev source
The review identifies Allan-Herndon-Dudley syndrome with MCT8 deficiency (Monocarboxylate transporter 8 deficiency, p. 25). It also describes severe neurological impairment and features of a thyroid hormone-deficient state in patients with MCT8 deficiency (Role of monocarboxylate transporter 8 in the brain, p. 35), supporting the syndrome as an illustration of disrupted signaling. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In fact, in a cross-sectional study based on the US National Health and Nutrition Examination Survey data base, serum T3 and fT3 levels were 10% lower in LT4-treated patients than in a control group matched for sex, age, ethnic background, and TSH levels [13].”
What the sources say
- Supportedcites [13] Peterson, 2016, Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?, J Clin Endocrinol Metab source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In keeping with this, markers of euthyroidism, such as serum cholesterol levels, mitochondrial content, and enzymatic activity within liver and skeletal muscle, better approximated values in control rats when sustained delivery of both LT4 and LT3 was employed.”
What the sources say
- Supportedcites [4] Werneck de Castro, 2015, Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine, J Clin Invest source
The Results section 'Systemic impact of lower serum T3 in T4-mono rats' (p. 3) states that only in the T4/T3-comb (subcutaneous pellet, steady-release) animals did mitochondrial content and alpha-GPD activity in liver and skeletal muscle normalize, and likewise that only in T4/T3-comb animals did serum cholesterol return to placebo-control levels (p. 3). The Introduction (p. 2) and Discussion (pp. 5, 8) restate that only combined continuous delivery of L-T4 and L-T3 fully normalized these T3-dependent metabolic markers, matching the claim's 'sustained delivery' qualifier. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
118 more claims · 8 with their cited sources checked
Create a free account to see all 233 claims and to verify the 196 references still open.
- It may state two separate claims as one. 69
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Almost all these blinded RCTs showed that QoL improved during combined liothyronine/levothyroxine treatment, but that it also improved to the same degree during levothyroxine monotherapy, demonstrating the strong placebo effect of thyroid hormones.”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“combination liothyronine/levothyroxine therapy has not been demonstrated to be superior to levothyroxine monotherapy in clinical trials. 42”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hypothyroid patients treated with levothyroxine monotherapy tend to have lower serum T3 concentrations and higher T4 levels than healthy people. 42,50”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [42]
In the citing paper
“Trials to date were heterogeneous in design, and most (but not all, see above) recruited patients with no rationale for benefit from the treatment; future trials need to be conducted in populations more likely to benefit from intervention with T3, to incorporate sensitive, thyroid-specific measures of quality of life, and with enough participants to ensure sufficient statistical power 64 .”
From A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism (2024) · cites this paper as [64]
Citations
Cites
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationGlobal epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Self-citationMolecular Aspects of Thyroid Hormone Actions
Cheng, S.-Y., Leonard, J. L., & Davis, P. J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0007 · Cited by 1,384
Cognition assessment using the NIH Toolbox
Weintraub, S., Dikmen, S. S., Heaton, R. K., Tulsky, D. S., Zelazo, P. D., Bauer, P. J., Carlozzi, N. E., Slotkin, J., Blitz, D., Wallner-Allen, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872ded · Cited by 1,287
Vision assessment using the NIH Toolbox
Varma, R., McKean-Cowdin, R., Vitale, S., Slotkin, J., & Hays, R. D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182876e0a · Cited by 1,178
Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0344-y · Cited by 845
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686
Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., & Rothman, M. (2000) · Quality of Life Research · doi:10.1023/a:1008996223999 · Cited by 577
A New Approach to the Measurement of Quality of Life: The Patient-Generated Index
Ruta, D. A., Garratt, A. M., Leng, M., Russell, I. T., & MacDonald, L. M. (1994) · Medical Care · doi:10.1097/00005650-199411000-00004 · Cited by 527
Research works printed but not linked: 6
- Jo, 2019, Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain, J Clin Invest, 129, 230, 10.1172/jci123176 · DOI · Paper page
- Escobar-Morreale, 2005, Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone, Ann Intern Med, 142, 412, 10.7326/0003-4819-142-6-200503150-00007 · DOI · Paper page
- Jonklaas, 2008, Triiodothyronine levels in athyreotic individuals during levothyroxine therapy, JAMA, 299, 769, 10.1001/jama.299.7.769 · DOI · Paper page
- Watt T (CaplanM, editor). Book Chapter: Measuring impact of benign thyroid diseases on quality of life. Reference Module in Biomedical Sciences. Elsevier; 2018.ISBN: 978-0-12-801238-3.
- O’Boyle CA , HickeyA, JoyceCR, O’MalleyK, HiltbrunnerB. Evaluation of Individual Quality of Life (SEIQoL). Administration manual. Dublin: Royal College of Surgeons in Ireland; 1993. pp. 1–73. In: https://repository.rcsi.com/articles/The_Schedule_for_the_Evaluation_of_Individual_Quality_of_Life_SEIQoL_Administration_Manual_/10770242, ed.
- Siegmund, 2004, Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism, Clin Endocrinol (Oxf), 60, 750, 10.1111/j.1365-2265.2004.02050.x · DOI · Paper page
Cited by
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Hashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationDeiodinases control local cellular and systemic thyroid hormone availability
Köhrle, J., & Frädrich, C. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.024 · Cited by 133
Ovčariček, P. P., Görges, R., & Giovanella, L. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.11.002 · Cited by 100
Metadata
- Authors
- Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., Watt, T., & Dayan, C. M.
- Affiliations
- Georgetown University (US)
- University of Chicago (US)
- University of Pennsylvania (US)
- Virginia Commonwealth University (US)
- Amsterdam University Medical Centers (NL)
- University of Duisburg-Essen (DE)
- Rush University (US)
- Herlev Hospital (DK)
- University Health Network (CA)
- Copenhagen University Hospital (DK)
- Cardiff University (GB)
- ORCID
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2021-02-16
- Volume
- 10
- Issue
- 1
- Pages
- 10-38
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC7983670
- OpenAlex
- W3133140094
- Cited by
- 78
- References
- 114
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 11 · 2022: 22 · 2021: 9
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute on Aging (K24AG042765)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- levothyroxine, liothyronine, combination thyroid hormone therapy, hypothyroidism, thyroid hormone replacement, clinical trial design, patient-reported outcomes, patient preferences, trial power
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. https://app.cochat.ai/papers/10.1159/000512970
- The paper
- Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., Watt, T., & Dayan, C. M. (2021). Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. European Thyroid Journal. https://doi.org/10.1159/000512970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.